NecstGen’s Post

Cell therapies are revolutionizing medicine. Learn the science behind how they're manufactured and more with "Making a Cell Therapy: Principles and Practice of Manufacturing" from the MIT Department of Biological Engineering. Open now, self-paced. Enroll at https://bit.ly/3Z4TEV6 #Education #CellTherapies #BiologicalEngineering #OnlineCourses

🚀 The cell therapy industry is on the brink of a digital revolution… At the recent ISCT conference in Vancouver, Asimov's Head of Process Modelling, Will Johnson, showcased how advanced digital technologies are transforming bioprocess development and vector design. We’ve written up a summary for you, which you can find at https://hubs.ly/Q02Gdr8J0 Here are some of the key takeaways: 1️⃣ Computational modeling and machine learning are being integrated into every step of cell therapy production 2️⃣ Digital tools are enabling end-to-end optimization of viral vector bioprocesses 3️⃣ These advancements are dramatically improving efficiency and outcomes in cell therapy development The future of cell therapy is digital. Are you ready for this transformation? #CellTherapy #DigitalRevolution #Innovation

Check out our Cell and Gene Therapy team's latest thoughts on decentralized manufacturing approaches!

Cerebral organoid activity can be measured on 3D high-density multi-electrode array chip, How you ask, here is the protocol that our research team has developed https://lnkd.in/geq9GfG5

Working or interested in cell therapy based applications? Then this efficient protocol for processing and cryopreservation of your cell cultures is sure to be a valuable resource. ✨https://lnkd.in/gtnujxht Whether you're working with adherent or suspension cells, this procedure applies to small or large-scale manufacturing. Utilizing cutting-edge tools like the Finia® Fill and Finish System and controlled-rate freezers, the protocol guarantees optimal temperature control and high cell viability. 🌡️ Unleash the potential of your cell therapies – because every breakthrough starts with the right protocol! Work by: Ye Li,Hazel Stevens, Srikanth Sivaraman, PhD, Logan Porter, Allison Hoffman, Stuart Gibb, Ph.D, Shivaram Selvam, and Annie Bowles-Welch, PhD at MC3M (Marcus Center for Cell Characterization and Manufacturing) and Terumo Blood and Cell Technologies. #Biomanufacturing #CellTherapy #research #lifesciences 🧪✨ Have a protocol that can contribute to scientific clarity and reproducibility ? Visit us at https://lnkd.in/dt_igxRi and explore publishing with Bio-protocol! #lifesciences #bio #protocol #bioprotocol #openaccess #reproducibility

📢 Revolutionizing Upstream Bioprocessing: Boost Production and Achieve Scalability with Advanced Technologies 🔍 Upstream bioprocessing can be more intense and stable with holistic monitoring and control technologies. 🔬 Experts discuss platforms for industrializing cell therapy, machine-learning-assisted clone selection, microbioreactors for modeling large-scale processes, and streamlined process analytical technology. 📊 These options can boost production and achieve a state of readiness in biomanufacturing. 🚀 The goal is to have a reliable and scalable platform from the start. 🧪 Artificial intelligence can help predict clone performance in intensified processes. 🌱 Clones optimized for fed-batch processes may not be ideal for perfusion processes. ⚙️ True perfusion processes should start with clones optimized for perfusion conditions. #BioprocessUpdates #UpstreamBioprocessing #HolisticMonitoring #ControlTechnologies #CellTherapy #MachineLearning #Microbioreactors #ProcessAnalyticalTechnology #BoostProduction #Biomanufacturing #ArtificialIntelligence #ClonePerformance #FedBatchProcesses #PerfusionProcesses #ReliablePlatform #ScalablePlatform ▷ Read the full article here: 📎 https://lnkd.in/dDWTgQ_S

Since transitioning from academia to industry in the field of cell therapy for #NeuroRegeneration 🧠, I’ve encountered key differences that highlight the complex journey from lab discovery to a market-ready product. Here are some insights that might be useful for others: Optimization for Marketability: Moving from academic protocols to industrial processes presents new challenges🔬. It requires meticulous optimization, upscaling, and rigorous quality control at every stage to ensure consistency and efficacy. Challenges in Upscaling: Scaling up is more than just increasing volume; it can lead to unanticipated shifts in cell phenotype and function. Factors like oxygen gradients, nutrient diffusion, and mechanical stresses can significantly alter cell behavior, necessitating careful monitoring and adjustments. 🔍 Bridging Preclinical to Human Models: While mouse models are foundational, human cell-based models, such as organoids, are critical for accurately predicting how therapies will perform in humans. These models provide essential insights into human-specific responses, making them invaluable in preclinical testing. Model Variety for Comprehensive Data: No single model is perfect, but combining various in vitro 🧠 and in vivo 🐭approaches offers a holistic understanding of therapy performance. This diversity of testing is crucial before advancing to clinical trials, ensuring that all potential outcomes are thoroughly explored. As a company moves beyond product development, navigating the clinical trial stage becomes even more intricate. My next post will deal with insights I've gained from that stage of the process. #CellTherapy #NeuroRegeneration #Biotech #Research

Is decentralized manufacturing the key to widespread adoption of cell therapy? Read below to see our take. #celltherapy #manufacturing #healthadvances

𝐅𝐥𝐨𝐰 𝐂𝐲𝐭𝐨𝐦𝐞𝐭𝐫𝐲 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐇𝐢𝐭 $10.3 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2032 Download an Illustrative overview: https://lnkd.in/dszjxcm6 The size of global 𝐟𝐥𝐨𝐰 𝐜𝐲𝐭𝐨𝐦𝐞𝐭𝐫𝐲 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐧 𝐭𝐞𝐫𝐦𝐬 𝐨𝐟 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 𝐰𝐚𝐬 𝐞𝐬𝐭𝐢𝐦𝐚𝐭𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐰𝐨𝐫𝐭𝐡 $5.1 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 2024 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 $10.3 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2032, 𝐠𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 9.2% from 2024 to 2032 Players operating in the global #flowcytometrymarket are increasingly focused on developing and #commercializingtechnologically advanced flow cytometry products that offer streamlined #workflows, ease of operability, and improved turnaround times. Continuous innovations in flow cytometry instruments, such as the development of multiplexing capabilities, higher throughput systems, and enhanced data analysis software, also drive market growth. These advancements improve the efficiency, sensitivity, and accuracy of flow cytometry assays, making them more attractive for research and clinical applications. For instance, in April 2024, Becton, Dickinson and Company (US) introduced 𝐁𝐃 𝐅𝐀𝐂𝐒𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐒8 𝐂𝐞𝐥𝐥 𝐒𝐨𝐫𝐭𝐞𝐫, which features 𝐁𝐃 𝐂𝐞𝐥𝐥𝐕𝐢𝐞𝐰 𝐈𝐦𝐚𝐠𝐞 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐁𝐃 𝐒𝐩𝐞𝐜𝐭𝐫𝐚𝐥𝐅𝐗 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲; these new #spectralcell sorters offer #realtimeimaging and #spectralflowcytometry capabilities. 𝐄𝐧𝐭𝐞𝐫𝐩𝐫𝐢𝐬𝐞𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐰𝐢𝐭𝐡𝐢𝐧 𝐭𝐡𝐢𝐬 𝐢𝐧𝐝𝐮𝐬𝐭𝐫𝐲: Sysmex Partec Flow Cytometry        Beckman Coulter Life Sciences      Sysmex America, Inc.      Q² Solutions      Cytek Biosciences      Dotmatics      siParadigm Diagnostic Informatics      Sony Biotechnology Inc.      Invivoscribe      Hematogenix      Elabscience Bionovation Inc.      Dr Lal PathLabs Sysmex Asia Pacific   STAFF ICONS, LLC   Bigelow Laboratory for Ocean Sciences FlowJo  Synexa Life Sciences  Cerba Research      Insightful Science  Molecular Pathology Laboratory Network, Inc. (MPLN)      CSI Laboratories      GoPath Diagnostics     Unipath Specialty Laboratory      IndiFOSS      KCAS Bio - Philadelphia      Sysmex France      NanoFCM      Texcell      Rules-Based Medicine a Q² Solutions Company      Curiox Biosystems      bNovate Technologies SA      TissueGnostics      LABCLINICS, S.A      Biogenix Labs      Cytognos S.L.      Rarity Bioscience        Cairo Diagnostics, LLC   

Decentralization is emerging as a potentially promising strategy for addressing cell therapy manufacturing challenges. In this new blog from our colleagues at Health Advances, they delve into the intricacies of decentralized cell therapy manufacturing with practical examples of where this approach is being implemented. Read now to find out which products and companies stand to benefit the most from adopting decentralized manufacturing.